The dynamics of thrombin formation.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Arteriosclerosis, Thrombosis and Vascular Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.ATV.0000046238.23903.FCPMID 12524220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aspirin Alters the Cardioprotective Effects of the Factor XIII Val34Leu Polymorphism

  2003cited by this paper
• Factor V: a combination of Dr Jekyll and Mr Hyde.

  2003cited by this paper
• Thrombin functions during tissue factor-induced blood coagulation.

  2002cited by this paper
• A Model for the Stoichiometric Regulation of Blood Coagulation*

  2002cited by this paper
• Thrombosis and Hemorrhage

  2002cited by this paper
• Mechanism of factor VIIa-dependent coagulation in hemophilia blood.

  2002cited by this paper
• Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation.

  2001cited by this paper
• Platelets and Phospholipids in Tissue Factor-initiated Thrombin Generation

  2001cited by this paper
• Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation

  2001cited by this paper
• The Role of Factor XI in Thrombin Generation Induced by Low Concentrations of Tissue Factor

  2001cited by this paper
• Gene Therapy for Cardiovascular Disorders

  2001cited by this paper
• PlA2 Polymorphism of &bgr;3 Integrins Is Associated With Enhanced Thrombin Generation and Impaired Antithrombotic Action of Aspirin at the Site of Microvascular Injury

  2001cited by this paper
• Crystal Structure Studies on Fibrinogen and Fibrin

  2001cited by this paper
• Blood coagulation at the site of microvascular injury: effects of low-dose aspirin.

  2001cited by this paper
• Factor V: Dr. Jeckyll and Mr. Hyde.

  2001cited by this paper
• Antiplatelet agents in tissue factor-induced blood coagulation.

  2001cited by this paper
• The role of platelets in decrypting monocyte tissue factor.

  2001cited by this paper
• Oral Anticoagulation Thresholds

  2001cited by this paper
• Congenital afibrinogenemia.

  2000cited by this paper
• Blood Coagulation Factor X Deficiency Causes Partial Embryonic Lethality and Fatal Neonatal Bleeding in Mice

  2000cited by this paper
• Measurement of Tissue Factor Activity in Whole Blood

  2000cited by this paper
• How Much Factor V Is Enough?

  2000cited by this paper
• Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa.

  2000cited by this paper
• Novel, Bedside, Tissue Factor–Dependent Clotting Assay Permits Improved Assessment of Combination Antithrombotic and Antiplatelet Therapy

  2000cited by this paper
• Regulation of Prothrombinase Activity by Protein S

  1999cited by this paper
• Blood-borne tissue factor: another view of thrombosis.

  1999cited by this paper
• The effect of membrane composition on the hemostatic balance.

  1999cited by this paper
• An Integrated Study of Fibrinogen during Blood Coagulation*

  1999cited by this paper
• "Normal" thrombin generation.

  1999cited by this paper
• Tissue-specific expression of functional platelet factor XI is independent of plasma factor XI expression.

  1998cited by this paper
• Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice.

  1998cited by this paper
• Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice.

  1998cited by this paper
• A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor*

  1998cited by this paper
• Blood coagulation in hemophilia A and hemophilia C.

  1998cited by this paper
• Prothrombin deficiency results in embryonic and neonatal lethality in mice.

  1998cited by this paper
• Mice lacking factor VII develop normally but suffer fatal perinatal bleeding

  1997cited by this paper
• Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice.

  1997cited by this paper
• An in vitro analysis of the combination of hemophilia A and factor V(LEIDEN).

  1997cited by this paper
• Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases*

  1997cited by this paper
• Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation

  1997cited by this paper
• Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II*

  1997cited by this paper
• Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN *

  1997cited by this paper
• Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor.

  1996cited by this paper
• Factor XI deficiency.

  1996cited by this paper
• Targeted disruption of the murine tissue factor gene results in embryonic lethality.

  1996cited by this paper
• Blood clotting in minimally altered whole blood.

  1996cited by this paper
• Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V

  1996cited by this paper
• 10 Factor XI deficiency

  1996cited by this paper
• Kinetics of human factor VII activation.

  1996cited by this paper
• A Thr359Met mutation in factor VII of a patient with a hereditary deficiency causes defective secretion of the molecule.

  1996cited by this paper
• Genetic analysis and functional characterization of prothrombins Corpus Christi (Arg382-Cys), Dhahran (Arg271-His), and hypoprothrombinemia.

  1996cited by this paper
• TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex*

  1996cited by this paper
• Purification and Characterization of TAFI, a Thrombin-activable Fibrinolysis Inhibitor (*)

  1995cited by this paper
• Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

  1995cited by this paper
• Tissue factor in plasma of patients with disseminated intravascular coagulation

  1994cited by this paper
• A model for the tissue factor pathway to thrombin. I. An empirical study.

  1994cited by this paper
• The mechanism of inactivation of human factor V and human factor Va by activated protein C.

  1994cited by this paper
• A model for the tissue factor pathway to thrombin. II. A mathematical simulation.

  1994cited by this paper
• Impaired human tissue factor-mediated activity in blood clotting factor VIINagoya (Arg304-->Trp). Evidence that a region in the catalytic domain of factor VII is important for the association with tissue factor.

  1994cited by this paper
• Congenital afibrinogenemia

  1994cited by this paper
• Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.

  1993cited by this paper
• Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin.

  1993cited by this paper
• Synthetic substrates for human factor VIIa and factor VIIa-tissue factor.

  1993cited by this paper
• Factor XI Deficiency

  1993cited by this paper
• Complex-dependent inhibition of factor VIIa by antithrombin III and heparin.

  1993cited by this paper
• Components and Assembly of the Factor X Activating Complex

  1992cited by this paper
• The roles of fibrinogen and fibrin in hemostasis and thrombosis.

  1992cited by this paper
• The evaluation of complex-dependent alterations in human factor VIIa.

  1992cited by this paper
• Role of the membrane surface in the activation of human coagulation factor X.

  1992cited by this paper
• The roles of fibrinogen and fibrin in hemostasis and thrombosis.

  1992cited by this paper
• Comparison of anticoagulant and procoagulant activities of stimulated platelets and platelet-derived microparticles.

  1991cited by this paper
• Surface‐Dependent Reactions in the Propagation Phase of Blood Coagulation

  1991cited by this paper
• The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation

  1991cited by this paper
• Factor XI activation in a revised model of blood coagulation

  1991cited by this paper
• Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples.

  1991cited by this paper
• Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.

  1991cited by this paper
• Activation of human factor V by factor Xa and thrombin.

  1990cited by this paper
• The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.

  1990cited by this paper
• Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor.

  1990cited by this paper
• Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity.

  1989cited by this paper
• Partial gene deletion in a family with factor X deficiency.

  1989cited by this paper
• In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma.

  1989cited by this paper
• Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor

  1989cited by this paper
• Hemostasis and Thrombosis: Basic Principles and Clinical Practice

  1988cited by this paper
• Tissue factor and hemostasis.

  1988cited by this paper
• Hemostasis and thrombosis: Basic principles and clinical practice

  1987cited by this paper
• Complete cDNA and derived amino acid sequence of human factor V.

  1987cited by this paper
• Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.

  1986cited by this paper
• Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds.

  1985cited by this paper
• The role of activated human platelets in prothrombin and factor X activation.

  1985cited by this paper
• Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency.

  1984cited by this paper
• Inactivation of human coagulation factor V by activated protein C.

  1983cited by this paper
• Changes in membrane phospholipid distribution during platelet activation.

  1983cited by this paper
• Radioimmunoassay of factor V in human plasma and platelets.

  1982cited by this paper
• Thrombin-catalyzed activation of human coagulation factor V.

  1982cited by this paper
• Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.

  1982cited by this paper
• Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C.

  1982cited by this paper
• Subcellular Localization and Secretion of Factor V by Human Platelets

  1981cited by this paper
• [Parahemophilia-factor V deficiency].

  1980cited by this paper
• Factor Va-dependent binding of factor Xa to human platelets.

  1980cited by this paper

• Spatiotemporal dynamics of mammalian wound healing

  2026cites this paper
• Programmable Aptamer-Controlled Fibrinogenesis Using Dynamic DNA Networks and Synthetic Transcription Machineries.

  2026cites this paper
• Synthetic urinary biomarker probes for disease detection and monitoring

  2026cites this paper
• Synthetic Peptide-Based Thrombin Inhibitors: a Potential Anticoagulant Approach

  2025cites this paper
• Strategies and Research Progress of Surface Antithrombotic Polymer Coating Under Inflammatory Conditions

  2025cites this paper
• Beyond prothrombin time and activated partial thromboplastin time: coagulation in vivo-an illustrated review.

  2025cites this paper
• Pediatric Venous Thromboembolism: Considerations for the Interventional Radiologist

  2025cites this paper
• The Role of HSP47 in Thrombotic Disorders: Molecular Mechanism and Therapeutic Potential

  2025cites this paper
• Pulmonary edema following subarachnoid hemorrhage is associated with impairment of pulmonary vascular endothelial glycocalyx

  2025cites this paper
• Relationship between hypercoagulability and mesenteric ischemia early after cardiac surgery.

  2025cites this paper
• Conformation of factor Xa in solution revealed by single molecule spectroscopy.

  2024cites this paper
• Dependence of clot structure and fibrinolysis on apixaban and clotting activator

  2024cites this paper
• Advances in microRNA regulation of deep vein thrombosis through venous vascular endothelial cells (Review).

  2024cites this paper
• The Prothrombin-Prothrombinase Interaction.

  2024cites this paper
• A Computational Model of the Secondary Hemostasis Pathway in Reaction Systems

  2024cites this paper
• Highly sensitive and label-free protein immunoassay-based biosensor comprising infrared metamaterial absorber inducing strong coupling.

  2024cites this paper
• Thrombin - A Molecular Dynamics Perspective.

  2023cites this paper
• Nonallosteric activation of posttranslational modification enzymes by active site-directed inhibitors

  2023cites this paper
• Andexanet alfa or prothrombin complex concentrate for acute reversal of oral factor Xa inhibitors: monitoring of antidote effects.

  2023cites this paper
• Monitoring prothrombin activation in plasma through loss of FRET.

  2023cites this paper
• Enhanced in vivo and ex vivo thrombin generation after lower-leg trauma, but not after knee arthroscopy

  2023cites this paper
• Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen

  2023cites this paper
• ANALYSIS OF THE BLOOD HYPERCOAGULATION RISK IN PATIENTS WITH ISCHEMIC ATHEROTHROMBOTIC STROKE DEPENDING OF THE VDR GENE POLYMORPHISMS.

  2023cites this paper
• The endothelial glycocalyx—All the same? No, it is not

  2023cites this paper
• Endothelial PAR2 activation evokes resistance artery relaxation

  2023cites this paper
• Transitioning to Unfractionated Heparin in Treatment of Non-ST-Segment Elevation Myocardial Infarction Patients on Direct Oral Anti-Xa Inhibitors.

  2023cites this paper
• Thrombin, a Key Driver of Pathological Inflammation in the Brain

  2023cites this paper
• Hemostatic capability of ultrafiltrated fresh frozen plasma compared to cryoprecipitate

  2023cites this paper
• Activity Sensing of Coagulation and Fibrinolytic Proteases.

  2022cites this paper
• “In Less than No Time”: Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy

  2022cites this paper
• Revised model of the tissue factor pathway of thrombin generation: Role of the feedback activation of FXI

  2022cites this paper
• Point of care coagulation management in anesthesiology and critical care.

  2022cites this paper
• Assessment of thrombin generation in horses using a calibrated automated thrombogram.

  2022cites this paper
• G-Quadruplex-Functionalized Gold Nanoparticles for a Real-Time Biomolecule Sensor with On-Demand Tunable Properties.

  2022cites this paper
• Investigation of differences in coagulation characteristics between hospitalized patients with SARS‐CoV‐2 Alpha, Delta, and Omicron variant infection using rotational thromboelastometry (ROTEM): A single‐center, retrospective, observational study

  2022cites this paper
• Comparison of Optical and Electrical Sensor Characteristics for Efficient Analysis of Attachment and Detachment of Aptamer

  2022cites this paper
• Endobronchial blood-patch: A novel technique for a persistent pleural air leak

  2022cites this paper
• Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran

  2022cites this paper
• Coagulation influencing liberation from respiratory support in patients with coronavirus disease 2019: a retrospective, observational study.

  2022cites this paper
• Experimental antithrombotic effect of medicinal plants: A critical review

  2022cites this paper
• Investigation of predictors of bleeding complications in COVID‐19 using rotational thromboelastometry (ROTEMⓇ): A retrospective study

  2022cites this paper
• Endothelial Transcytosis in Acute Lung Injury: Emerging Mechanisms and Therapeutic Approaches

  2022cites this paper
• Effects of Catheter, Stenosis and Thrombosis in Non-Newtonian Blood Flow Through Narrow Arteries with Clinical Applications: A Mathematical Model

  2022cites this paper
• Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro

  2022cites this paper
• Patient-Specific Modelling of Blood Coagulation

  2021cites this paper
• Evaluation of Platelet Activation by HIV Protease Inhibitors – The HIV-PLA II Study

  2021cites this paper
• Occurrence and management of severe bleeding episodes in patients with hereditary factor X deficiency

  2021cites this paper
• Coagulopathy and Progression of Intracranial Hemorrhage in Traumatic Brain Injury: Mechanisms, Impact, and Therapeutic Considerations

  2021cites this paper
• Anticoagulant Dodecapeptide Suppresses Thrombosis In Vivo by Inhibiting the Thrombin Exosite-I Binding Site.

  2021cites this paper
• Antithrombin Resistance Rescues Clotting Defect of Homozygous Prothrombin-Y510N Dysprothrombinemia

  2021cites this paper
• Influence of high‐dose antithrombin on platelet function and blood coagulation

  2021cites this paper
• Evaluating interactions between hyperglycemia and clotting factors in patients suffering with SARS-CoV-2 infection

  2021cites this paper
• Antisense Tissue Factor Oligodeoxynucleotides Protected Diethyl Nitrosamine/Carbon Tetrachloride-Induced Liver Fibrosis Through Toll Like Receptor4-Tissue Factor-Protease Activated Receptor1 Pathway

  2021cites this paper
• Astragalin Inhibits Cigarette Smoke-Induced Pulmonary Thrombosis and Alveolar Inflammation and Disrupts PAR Activation and Oxidative Stress-Responsive MAPK-Signaling

  2021influential citation
• Protein Labeling and Crosslinking by Covalent Aptamers.

  2021cites this paper
• Endothelial cells and coagulation

  2021cites this paper
• The use of ‘viscoelastic tests’ in driving transfusion needs in major trauma patients

  2021cites this paper
• Coagulation in Lymphatic System

  2021cites this paper
• Effects of porosity in four-layered non-linear blood rheology in constricted narrow arteries with clinical applications

  2020cites this paper
• Chronometric vs. Structural Hypercoagulability

  2020cites this paper
• TWO-PHASE NONLINEAR RHEOLOGICAL ANALYSIS OF BLOOD FLOW IN SMALL DIAMETER BLOOD VESSELS WITH CONSTRICTION

  2020cites this paper
• Evolving concepts and strategies in the management of polytrauma patients.

  2020cites this paper
• Hemostasis

  2020cites this paper
• Grading Clinical Coagulopathy and Predicting Massive Transfusion

  2020cites this paper
• Changing concepts of clotting mechanism of blood: From cascade model to cell-based model

  2020cites this paper
• Normal hemostasis

  2020cites this paper
• How to screen and diagnose deep venous thrombosis (DVT) in patients hospitalized for or suspected of COVID-19 infection, outside the intensive care units

  2020cites this paper
• Early thromboelastography in acute traumatic coagulopathy: an observational study focusing on pre-hospital trauma care

  2020cites this paper
• Surface plasmon resonance-based aptasensor for direct monitoring of thrombin in a minimally processed human blood

  2020cites this paper
• Changes in Coagulation following Brain Injury

  2020cites this paper
• Clotting factors: Clinical biochemistry and their roles as plasma enzymes.

  2020cites this paper
• Wave propagation for a reduced model of blood coagulation

  2020cites this paper
• New diagnostic approaches for venous thromboembolism and thrombophilia

  2020cites this paper
• Thrombin Generation and other hemostatic parameters in patients with atrial fibrillation in use of warfarin or rivaroxaban

  2020cites this paper
• Fibrin Matrices as (Injectable) Biomaterials: Formation, Clinical Use, and Molecular Engineering.

  2019cites this paper
• Ability of Fibrin Monomers to Predict Progressive Hemorrhagic Injury in Patients with Severe Traumatic Brain Injury

  2019cites this paper
• Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study

  2019cites this paper
• The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition

  2019cites this paper
• Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial

  2019cites this paper
• Mathematical Modeling of Thrombin Generation and Wave Propagation: From Simple to Complex Models and Backwards

  2019cites this paper
• In vivo assessment of anticoagulant and antiplatelet effects of Syzygium cumini leaves extract in rabbits

  2019cites this paper
• Measurements of endogenous thrombin potential using the CAT method in cats: Reference values and influence of the direct factor Xa inhibitor apixaban.

  2019cites this paper
• Systems pharmacology in modelling complex scenarios: Opportunities and challenges

  2019cites this paper
• Synthesis and biological evaluation of Isosteviol derivatives as FXa inhibitors.

  2019cites this paper
• Fibrin and Fibrinolysis in Cancer

  2019cites this paper
• [Modern coagulation management in bleeding trauma patients : Point-of-care guided administration of coagulation factor concentrates and hemostatic agents].

  2019cites this paper
• Global coagulation assays in hemophilia A: A comparison to conventional assays

  2019cites this paper
• The Cardioprotective Signaling Activity of Activated Protein C in Heart Failure and Ischemic Heart Diseases

  2019cites this paper
• Assessment of Thrombin Generations in Patients with Chronic Liver Diseases

  2019cites this paper
• A prospective evaluation of thromboelastometry (ROTEM) to identify acute traumatic coagulopathy and predict massive transfusion in military trauma patients in Afghanistan

  2019cites this paper
• Clustering of Thrombin Generation Test Data Using a Reduced Mathematical Model of Blood Coagulation

  2019cites this paper
• L' intérêt du dosage des monomères de fibrine en traumatologie pour prédire la survenue d'une hémorragie grave

  2019cites this paper
• Prothrombin Arg541Trp Mutation Leads to Defective PC (Protein C) Pathway Activation and Constitutes a Novel Genetic Risk Factor for Venous Thrombosis

  2019cites this paper
• Moderne Gerinnungstherapie beim blutenden Schwerverletzten

  2019cites this paper
• Management of Massive Blood Loss in trauma and trauma-induced coagulopathy

  2018cites this paper
• Advances in Mechanisms, Diagnosis and Treatment of Coagulopathy and Progression of Hemorrhage After Traumatic Brain Injury

  2018cites this paper
• 2017 Scientific Sessions Sol Sherry Distinguished Lecture in Thrombosis: Factor XI as a Target for New Anticoagulants

  2018cites this paper
• Retrospective comparison of standard clotting tests and novel clot waveform parameters in dogs using the turbidimetric ACL-TOP CTS 300 coagulation analyzer

  2018cites this paper
• Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology

  2018cites this paper
• Relationship between serum cortisol level and degree of false lumen thrombosis in patients with uncomplicated type B aortic dissection

  2018cites this paper